Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of BMS-986120 in Healthy Subjects and the Effect of BMS-986120 on the Pharmacokinetics of Midazolam in Healthy Subjects

Trial Profile

Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of BMS-986120 in Healthy Subjects and the Effect of BMS-986120 on the Pharmacokinetics of Midazolam in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs BMS 986120 (Primary) ; Midazolam
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 28 Oct 2014 Planned End Date changed from 1 Oct 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 28 Oct 2014 Planned primary completion date changed from 1 Oct 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top